Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia

Next Previous
Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daridorexant (Primary)
  • Indications Insomnia; Nocturia
  • Focus Therapeutic Use
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 14 Mar 2025 According to Idorsia Pharmaceuticals media release, data from the study were presented at Journal of Sleep Research.
  • 14 Mar 2025 Results presented in the Idorsia Pharmaceuticals Media Release.
  • 25 Jul 2024 According to Idorsia Pharmaceuticals media release, positive topline results in Phase 4 study in patients with insomnia and comorbid nocturia to be presented at upcoming scientific congresses.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top